版本:
中国

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T ( 东京证券交易所 )

3,548JPY
23 Aug 2019
涨跌 (%)

¥-3 (-0.08%)
收盘
¥3,551
开盘
¥3,545
当日最高
¥3,567
当日最低
¥3,531
成交量
2,759,200
平均成交量
5,331,203
52 周最高
¥4,943
52 周最低
¥3,493

概况

Takeda Pharmaceutical Company Limited是一家从事制药业务的日本公司。道德制药分部主要生产和销售糖尿病治疗药物、循环系统药物、抗癌药物、中枢神经系统疾病药物、消化系统药物、激素药物、骨质疏松药物、抗生素、抗过敏药物等药物制剂、维生素滴剂和疫苗等。消费者医疗分部主要生产和销售一般药品以及... (更多)

概况

Beta: 0.80
市值(百万): ¥5,755,279.00
已发行股本(百万): 1,576.36
股息: 90.00
股息收益率 (%): 4.93

财务指标

  4502.T Industry Sector
P/E (TTM): 21.24 29.73 33.85
EPS (TTM): 171.88 -- --
ROI: 1.48 13.04 12.69
ROE: 3.05 14.12 17.13

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters. 全文
08/14 13:45

Japan stocks edge up, weaker yen offsets Fed disappointment

TOKYO, Aug 1 Japan's Nikkei share average recouped early losses and ended marginally higher on Thursday, supported by a weaker yen which helped offset disappointment that the U.S. Federal Reserve is not embarking on a lengthy easing cycle. 全文
08/01 14:10

Japan stocks inch up, weak yen helps offset Fed disappointment

TOKYO, Aug 1 Japan's Nikkei share average recouped early losses and inched up on Thursday, supported by a weaker yen which helped offset disappointment that the U.S. Federal Reserve is not embarking on a lengthy easing cycle. 全文
08/01 10:00

日本股市:日经指数收低,受中美贸易谈判谨慎情绪和疲弱财报打压

路透东京7月31日 - 日本股市周三下滑,受到美国总统特朗普威胁中国不要拖延贸易谈判的打击,同时令人失望的财报打压汽车零部件供应商和银行股价。 全文
07/31 15:48

Nikkei falls on caution over U.S.-China trade talks, earnings misses

* Investors digest mixed earnings: Nintendo falls, Sony gains 全文
07/31 15:19

Deals of the day-Mergers and acquisitions

July 17 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday: 全文
07/18 04:05

Takeda kicks off sale of Western European drugs - sources

FRANKFURT/LONDON, July 17 Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters. 全文
07/18 00:55

UPDATE 2-Karyopharm Therapeutics prices blood cancer treatment after FDA approval

July 3 Karyopharm Therapeutics Inc on Wednesday set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. Food and Drug Administration. 全文
07/04 03:51

Takeda scraps late-stage amyloidosis study

June 5 Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals. 全文
06/06 05:01

Japan's Takeda expects binding offers for Latam business by end of May -sources

SAO PAULO, May 16 Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said. 全文
05/17 01:35

收益 vs. 预测